FXS figure 1
Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers 
March 03, 2020 12:07 ET | Zynerba Pharmaceuticals, Inc.
- Data Presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - Health State Utility Index Data Estimate the Significant Health Burden of FXS, and Suggest the...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome
February 26, 2020 06:50 ET | Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
GL_Logo_Vertical.png
Analog Legacy Protocol Enhancements
October 22, 2019 12:09 ET | GL Communications Inc.
GAITHERSBURG, Md., Oct. 22, 2019 (GLOBE NEWSWIRE) -- GL Communications Inc., a global leader in telecom test and measurement solutions, addressed the press regarding the T1 E1 Protocol Analyzer...
ADAMS 12 month
Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
December 12, 2018 17:30 ET | Zynerba Pharmaceuticals, Inc.
- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - - Presentation Today at the 57th Annual...